316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A

• Aurélien Marabelle,
• Martin Wermke,
• Aude de Gassart,
• Daniel Olive,
• Patrick Brune,
• Emmanuel Valentin,
• Paul Frohna,
• Christiane Jungels,
• Norbert Vey,
• Elena Garralda,
• Marina Iché

Affiliations

Aurélien Marabelle

4 Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France

Martin Wermke

Aff11 Early Clinical Trial UnitUniversity Cancer Center Dresden Germany

Aude de Gassart

1ImCheck Therapeutics, Marseille, France

Daniel Olive

2CRCM, Marseille, France

Patrick Brune

1Imcheck Therapeutics, Marseille, France

Emmanuel Valentin

1Imcheck Therapeutics, Marseille, France

Paul Frohna

1Imcheck Therapeutics, Marseille, France

Christiane Jungels

2Institut Jules Bordet, Brussels, Belgium

Norbert Vey

4Institut Paoli-Calmettes, Marseille, France

Elena Garralda

6Vall d’Hebron Institute of Oncology, Barcelona, Spain

Marina Iché

8ILife Consulting, Paris, France